Considering Real-World Applications With ctDNA
Shared insight on how circulating tumor DNA may be used in real-world clinical practice to improve the value of cancer care.
Impact of ctDNA on the Management of Breast Cancer
Focusing broadly on breast cancer, expert oncologists detail how ctDNA may impact patient monitoring and treatment decisions moving forward.
Scenario 2: Use of ctDNA to Monitor High-Risk TNBC
Moving on to the second patient scenario, panelists elucidate the value of ctDNA in patients with triple-negative breast cancer.
Nuancing the Benefit of Circulating Tumor DNA
In the context of clinical trial data and personal experience, experts weigh the value of circulating tumor DNA as a tool in cancer care.
Clinical Trial Data on Use of ctDNA Assays
Experts share their perspective on clinical trial data driving the use of circulating tumor DNA in various settings of cancer care.
Identifying Use of ctDNA Across Tumor Types
Focusing on breast cancer, lung cancer, and GI cancers respectively, expert oncologists review the utility of circulating tumor DNA assays.
Understanding the Mechanisms and Use of ctDNA and MRD Testing
Expert panelists elucidate the mechanisms of ctDNA and MRD testing, providing a broad perspective on how they are used in cancer care.
Future Role of ctDNA in CRC: Surveillance and Treatment Selection
Shared insight on the potential roles of ctDNA and MRD testing in the monitoring and treatment of patients with colorectal cancer.
Scenario 1: ctDNA to Determine Use of Adjuvant Chemotherapy in Stage II CRC
Centering discussion on a patient scenario of stage II colorectal cancer, expert oncologists consider how ctDNA may inform use of adjuvant chemotherapy in this setting.
Oncology Peer Review On-The-Go: Tanios Bekaii-Saab, MD, and Experts Examine Therapy Resistance in CRC
Tanios Bekaii-Saab, MD, talks with Kristen Ciombor, MD, MSCI, and John Strickler, MD, about targeted therapy resistance, rechallenge, and acquired resistance mutations in colorectal cancer.
Oncology Peer Review On-The-Go: Tanios Bekaii-Saab, MD, and Colleagues Discuss GOZILA Platform for CRC
Tanios Bekaii-Saab, MD, details the GOZILA platform for colorectal cancer with experts Kristen Ciombor, MD, MSCI, and John Strickler, MD.
Oncology Peer Review On-The-Go: Tanios Bekaii-Saab, MD, Talks COLOMATE Platform in CRC With Experts
Tanios Bekaii-Saab, MD, sits with Kristen Ciombor, MD, MSCI, and John Strickler, MD, to examine the COLOMATE platform for patients with colorectal cancer.
Leading Gastrointestinal Cancer Experts Discuss Targeted Therapies and Landscape of Treatment
Tanios Bekaii-Saab, MD; Kristen Ciombor, MD, MSCI; and John Strickler, MD, detail key developments and needs in the gastrointestinal cancers landscape.
Addressing Resistance to Targeted Therapies in Metastatic Colorectal Cancer
Investigators discuss the use of targeted therapies to treat metastatic colorectal cancer.
The Current Molecular Treatment Landscape of Advanced Colorectal Cancer and Need for the COLOMATE Platform
Patients with colorectal cancer could benefit from the COLMATE platform as it allows for opportunities in clinical trial enrollment.